Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
May 12, 2022 16:06 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the Journal of Hepatology ...
May 11, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022

NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
May 05, 2022 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
April 04, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
March 17, 2022 16:25 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
March 17, 2022 16:06 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
March 10, 2022 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
February 10, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 18, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...